Company: TVRD
Filing Date: 2025-01-27
Form Type: S-4/A
Source: 0001104659-25-006050
Chunk: 313

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-01-27
Form: S-4/A
Chunk 313
---
 Tvardi’s executive officers and directors and such directors affiliated funds beneficially owned, in the aggregate, approximately 26.38% of the shares of Tvardi common stock. See the section titled “ Principal Stockholders of Tvardi ” beginning on page 374 of this proxy statement/prospectus for additional information. Certain Tvardi officers and directors, and their affiliates, have also entered into the Support Agreements in connection with the Merger. For a more detailed discussion of the Support Agreements, please see the section titled “ Agreements Related to the Merger ” beginning on page 196 . of this proxy statement/prospectus. Executive Officers of the Combined Company Following the Merger Immediately following the Merger, the executive management team of the combined company is expected to comprise of the following individuals with such additional officers as may be added by Tvardi or the combined company:

| ​                           | ​ | ​                                                     | ​ | ​                                                     |
| ​                           | ​ | Position with the                                     | ​ | ​                                                     |
| Name                        |   | Combined Company                                      |   | Current Position at Tvardi                            |
| Imran Alibhai, Ph.D.        | ​ | Chief Executive Officer and Director                  | ​ | Chief Executive Officer and Director                  |
| Dan Conn, J.D., M.B.A.      |   | Chief Financial Officer                               |   | Chief Financial Officer                               |
| John Kauh, M.D.             |   | Chief Medical Officer                                 |   | Chief Medical Officer                                 |
| Jeffrey Larson, Ph.D., DABT |   | Senior Vice President, Research & Development         |   | Senior Vice President, Research & Development         |
| Yixin “Joseph” Chen, Ph.D.  | ​ | Vice President, Chemistry, Manufacturing and Controls | ​ | Vice President, Chemistry, Manufacturing and Controls |

Directors of the Combined Company Following the Merger At the Effective Time, the combined company is expected to initially have a seven-member board of directors, comprising (a) Sujal Shah, Michael Wyzga, Wallace Hall, Shaheen Wirk and Imran Alibhai, each as an Tvardi designee and (b) one member to be designated by Cara prior to Closing, with one vacancy, to be designated by Tvardi if prior to the closing of the Merger or by the combined company if following the consummation of the Merger, each until their respective successors are duly elected or appointed and qualified or